Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.

Multiparametric MRI cuts rate of unnecessary repeat prostate biopsies

04 Oct 2018

Use of multiparametric magnetic resonance imaging (MRI) significantly lowers the number of unnecessary repeat prostate biopsies in about 50 percent of cases in which a Prostate Imaging Reporting and Data System (PI-RADS) score of ≥3 is used, a recent study has shown.

“At the same time patients should be informed of the 16.2 percent and 39.7 percent false-negative rates of clinically significant prostate cancer for targeted fusion prostate biopsy of PI-RADS 3 and 4 lesions, respectively,” the authors said.

Of the 1,032 patients, 372 (36 percent) had T1c prostate cancer, and 272 (73.1 percent) of such cases were classified as clinically significant prostate cancer.

The respective diagnosis of clinically significant prostate cancers following saturation prostate biopsy vs targeted fusion prostate biopsy and a PI-RADS score of ≥3 vs targeted fusion prostate biopsy and a PI-RADS score of ≥4 was 95.6 percent vs 83.8 percent vs 60.3 percent (p<0.0001).

Of the 272 clinically significant prostate cancers, 12 (4.5 percent) were missed by saturation prostate biopsy vs 44 (16.2 percent) and 108 (39.7 percent) by targeted fusion prostate biopsy and a PI-RADDS score of ≥3 or a score of ≥4, respectively (p<0.0001).

Multiparametric MRI as a triage test would have spared 49.3 percent of patients compared with 73.6 percent of those using a PI-RADS cutoff of ≥3 or ≥4.

In this study, repeat saturation prostate biopsy (the reference test) was performed from January 2011 to February 2018 due to suspicion of cancer in 1,032 men with a median age of 63 years in whom median prostate-specific antigen was 8.6 ng/ml. Prior to saturation prostate biopsy, all patients underwent 3.0 Tesla pelvic multiparametric MRI. Additional targeted fusion prostate biopsy was done of lesions with a PI-RADS score of ≥3.

Editor's Recommendations
Most Read Articles
6 days ago
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Yesterday
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Elvira Manzano, Yesterday
Long-term treatment with the interleukin-5 receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Pearl Toh, 2 days ago
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.